The November 2026 issue features a Review on in vivo immunoengineering. Immune cells are modified directly within the body. Strategies for checkpoint blockade and cellular therapies are discussed in the context of direct in vivo programming of immune responses.
Related products
| Catalog No. | Product Name | Description | Target |
|---|---|---|---|
| HS870026 | Anti-Human PD-1 Reference Antibody (Pembrolizumab | Pembrolizumab (HS870026) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns. | CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, PD-1 |
Quick access
Contact Us
+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский